Drug-related hospital admissions in older adults: comparison of the Naranjo algorithm and an adjusted version of the Kramer algorithm



Beatrijs Mertens<sup>1,2\*</sup>, Julie Hias<sup>1,2\*</sup>, Laura Hellemans<sup>1,2</sup>, Karolien Walgraeve<sup>2</sup>, Isabel Spriet<sup>1,2</sup>, Thomas De Rijdt<sup>2</sup>, Jos Tournoy<sup>3,4</sup>, Lorenz Roger Van der Linden<sup>1,2</sup>

Drug-related admissions (DRAs) are an important cause of preventable harm in older adults<sup>1-4</sup>.

Multiple algorithms exist to assess causality of adverse drug reactions, including the Naranjo algorithm<sup>5</sup> an adjusted, easy-to-use version of the Kramer algorithm<sup>6-8</sup>



The performance of these tools in assessing DRA causality has not been robustly shown.

We aimed to evaluate the ability of the adjusted Kramer algorithm to adjudicate DRA causality

in geriatric inpatients



DRAs were assessed in a convenience sample of patients admitted to the acute geriatric wards of UZ Leuven.



DRAs were **identified** by expert consensus and **causality** was evaluated using the Naranjo and the adjusted Kramer algorithms.



For both algorithms, DRA adjudication was compared to the expert consensus by calculating the positive agreement.



A multivariable logistic regression analysis was performed to explore determinants for a DRA.



The maximal positive agreement with the expert consensus and the simplicity of the adjusted Kramer algorithm support its implementation as part of a structured DRA assessment approach in older adults.

<u>Affiliations:</u><sup>1</sup> Department of Pharmaceutical and Pharmacological Sciences, KU Leuven; <sup>2</sup> Pharmacy Department, University Hospitals Leuven; <sup>3</sup> Department of Public Health and Primary Care, KU Leuven; <sup>4</sup> Department of Geriatric Medicine, University Hospitals Leuven; \*shared first author; correspondence: beatrijs.1.mertens@uzleuven.be

<u>References:</u> <sup>1</sup> Lavan, et al. *Ther Adv Drug Saf.* 2016. <sup>2</sup> Cahir, et al. *BMJ Open.* 2017. <sup>3</sup> Oscanoa, et al. *Eur J Clin Pharmacol.* 2017. <sup>4</sup> Alhawassi, et al. *Clin Interv Aging.* 2014. <sup>5</sup> Naranjo, et al. *Clin Pharmacol Ther.* 1981. <sup>6</sup> Kramer, et al. *JAMA.* 1979. <sup>7</sup> Warlé-van Herwaarden, et al. *Pharmacoepidemiol Drug Saf.* 2015. <sup>8</sup> Leendertse, et al. *Arch Intern Med.* 2008.